Free Newsletter
Patch delivers killer doses
Dear FDA: Sometimes warnings don't get through--just witness the Surgeon General's stamp on cigarette packages. Or, closer to home, consider the cautionary language slapped onto painkiller patches.
According to an LA Times investigation, the fentanyl patches are still killing patients, despite the FDA's guidance that patches shouldn't be used for post-op treatment and should only be administered "with great caution." The newspaper raises the spectre of similar dose-related problems with delivering other drugs via patch, especially now that new technology promises to put patches to wider use.
The Ortho Evra contraceptive patch, for example, came under FDA fire because it exposes women to higher doses of a hormone linked to dangerous blood clots; recently, a doctors' group in Tennessee decided to stop prescribing it altogether, contributing to a 18-month plunge in sales of the Ortho-McNeil drug. Meanwhile, drug makers soldier on: Just last week, the FDA approved a Watson Pharmaceuticals version of the fentanyl pain patch.
- read the report from The Los Angeles Times
Related Articles:
FDA approves Watson's pain patch. Report
FDA issues warning for Ortho Evra patch. Report
Government probing link between pain patch and 120 deaths. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: